Based on the above findings about TRAF3 downstream signaling pathways, we first tested whether constitutive NF-κB2 activation can serve as a therapeutic target in B cell neoplasms with TRAF3 deletions or inactivating mutations. Here, TRAF3 is linked to B-cell neoplasm.